The Phase 3 trial (NCT06172361) investigating tofacitinib in combination with glucocorticoid for patients with Polymyalgia Rheumatica reached primary completion on 2025-09-30. This open-label, randomized controlled study is evaluating the efficacy and safety of this induction and tapering therapy over 52 weeks.
Background
Polymyalgia Rheumatica (PMR) is an inflammatory disorder that causes muscle pain and stiffness, primarily affecting the shoulders, neck, and hips. It predominantly affects older adults and can significantly impact quality of life. Current standard treatment often involves long-term glucocorticoid therapy, such as prednisone, which can lead to various side effects, including osteoporosis, diabetes, and cataracts. The development of new therapies that can effectively manage PMR while potentially reducing glucocorticoid dependency is an area of active research. Tofacitinib is an oral Janus kinase (JAK) inhibitor, currently approved for several autoimmune conditions, and is being explored for its potential in managing inflammatory diseases like PMR.
Trial design
The study, titled "Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica" (NCT06172361), is a Phase 3, open-label, 52-week randomized controlled trial. It has an estimated enrollment of 98 participants diagnosed with Polymyalgia Rheumatica. The trial design involves evaluating two intervention arms: one receiving prednisone+tofacitinib and another receiving prednisone alone. The study aims to assess the efficacy and safety of an induction and tapering therapy regimen involving tofacitinib alongside glucocorticoids in this patient population.
What this means
The primary completion of this Phase 3 trial for tofacitinib in Polymyalgia Rheumatica signifies that data collection for the study's primary endpoint has concluded. This is a crucial milestone in the drug development process, as it precedes the analysis of the collected data. Once the data is analyzed, results regarding the efficacy and safety of tofacitinib in combination with glucocorticoids for PMR will be anticipated. Positive findings could indicate a potential new treatment option that might offer benefits, such as reducing the reliance on long-term high-dose glucocorticoids, for patients suffering from this chronic inflammatory condition.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06172361, titled "Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica," was posted on 2025-09-30 on clinicaltrials.gov.